Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-774 and Bevacizumab in Stage IV Breast Cancer
NCT00054132Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2002
- Primary completion
- Apr 2015
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and bevacizumab in breast cancer, sponsored by National Cancer Institute. Primary endpoints: Level of EGFR Expression at 12 years and Response Rate, Defined as Complete Response (CR) + Partial Response (PR) at 12 years. Started Dec 2002; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00054132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054132.